Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

October

24

Data Highlighting nVNS for Treatment of Gastroparesis Symptoms Presented at American College of Gastroenterology Annual Meeting

Clinical trial suggests nVNS can reduce the use of rescue medications for exacerbations of...

17

electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue

Extension maintains listing through March 17, 2026 ROCKAWAY, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) — electroCore,...

11

electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology

ROCKAWAY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine...

10

Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress

VANQUISH Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of...

9

electroCore Announces Second Quarter 2023 Financial Results

Record second quarter 2023 net sales of $3.6 million, an increase of approximately 65% over second quarter...

31

electroCore, Inc. Announces $8.145 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules

ROCKAWAY, N.J., July 31, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”),...

25

gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD)

ROCKAWAY, N.J., July 25, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and...

18

electroCore Expands Intellectual Patent Portfolio for nVNS Technology

ROCKAWAY, N.J., July 18, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine...

13

electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC

ROCKAWAY, N.J., July 13, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine...

11

electroCore Provides Select Second Quarter 2023 Financial Guidance

Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65%...

6

gammaCore™ Selected for Study Funded by NFL and NFL Players Association on Alleviating Concussion Symptoms

Research grants jointly awarded to independent medical researchers studying alternative pain management treatments at...

27

electroCore’s TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project

ROCKAWAY, N.J., June 27, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and...

Recent developments

October

24

Data Highlighting nVNS for Treatment of Gastroparesis Symptoms Presented at American College of Gastroenterology Annual Meeting

October

17

electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue

October

11

electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology

October

10

Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress

August

9

electroCore Announces Second Quarter 2023 Financial Results

July

31

electroCore, Inc. Announces $8.145 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules

July

25

gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD)

July

18

electroCore Expands Intellectual Patent Portfolio for nVNS Technology

July

13

electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC

July

11

electroCore Provides Select Second Quarter 2023 Financial Guidance

July

6

gammaCore™ Selected for Study Funded by NFL and NFL Players Association on Alleviating Concussion Symptoms

June

27

electroCore’s TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project